SS-31 50mg Dosage Protocol | PeptideDosages.com

SS-31 (50 mg Vial) Dosage Protocol

SS-31 Dosage Chart

SS-31 is dosed at 5 mg–10 mg daily via subcutaneous injection in educational protocols. A 50 mg vial reconstituted with bacteriostatic water yields about 16.67 mg/mL. This information is for research and educational use only.

Reconstitute: Add 3.0 mL bacteriostatic water → ~16.67 mg/mL concentration for convenient dosing.

Typical daily range: 5–10 mg once daily (gradual titration); advanced protocols may reach 15–20 mg/day under supervision.

Easy measuring: At 16.67 mg/mL, 1 unit = 0.01 mL ≈ 167 mcg on a U‑100 insulin syringe.

Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

SS‑31 (elamipretide) is a mitochondria‑targeted tetrapeptide that selectively binds cardiolipin in the inner mitochondrial membrane[1], stabilizing electron transport chain complexes and reducing reactive oxygen species production while enhancing ATP synthesis[2]. This peptide has demonstrated protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy, and received FDA accelerated approval in 2025 as the first treatment for Barth syndrome[3]. This educational protocol presents a once‑daily subcutaneous approach using the cost‑effective 50 mg vial format with practical reconstitution for insulin‑syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read SS-31 Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Standard / Gradual Approach (3.0 mL = ~16.67 mg/mL)

Weeks 1–2

5 mg (5000 mcg)

30 units (0.30 mL)

Weeks 3–8

10 mg (10,000 mcg)

60 units (0.60 mL)

Frequency: Inject once daily subcutaneously at a consistent time. This 50 mg vial reconstituted with 3.0 mL provides a higher concentration, keeping all standard doses within moderate syringe volumes for convenience and accuracy.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.

Inject slowly down the vial wall; avoid vigorous shaking to prevent foaming.

Gently swirl/roll until fully dissolved (clear solution).

Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light; use within 4 weeks.

Advanced / Aggressive Approach (3.0 mL = ~16.67 mg/mL)

Weeks 3–4

Weeks 5–8

15 mg (15,000 mcg)

90 units (0.90 mL)

Optional Weeks 9–12

20 mg (20,000 mcg)

Split: 2 × 60 units (0.60 mL each)

Note: Advanced dosing (15–20 mg/day) is based on short‑term clinical trial protocols[4][5] for severe mitochondrial conditions and should only be pursued under medical supervision. At this concentration, doses up to 15 mg fit in a single syringe (90 units); 20 mg doses should be split into two separate subcutaneous injections at different sites. Clinical trials have not extensively evaluated SS‑31 beyond 12 weeks; extended use requires careful monitoring.

Supplies Needed

Plan based on an 8–12 week daily protocol with gradual titration using 50 mg vials.

8 weeks (Standard: 5–10 mg/day) ≈ 10 vials

12 weeks (Standard maintenance at 10 mg/day) ≈ 16 vials

12 weeks (Advanced: escalating to 15 mg/day) ≈ 21 vials

Per week (standard dosing): 7 syringes (1/day)

8 weeks: 56 syringes

12 weeks: 84 syringes

Advanced protocols with split injections may require 2 syringes per day for 20 mg doses

8 weeks (10 vials): 30 mL → 1 × 30 mL bottle

12 weeks (16 vials): 48 mL → 2 × 30 mL bottles

12 weeks (21 vials, advanced): 63 mL → 3 × 30 mL bottles

Per week: 14 swabs (2/day)

8 weeks: 112 swabs → recommend 2 × 100‑count boxes

12 weeks: 168 swabs → recommend 2 × 100‑count boxes

Protocol Overview

Concise summary of the once‑daily subcutaneous regimen.

Goal: Support mitochondrial function, enhance ATP production, and reduce oxidative stress in tissues with high metabolic demand[1][2].

Schedule: Daily subcutaneous injections for 8–12 weeks (clinical trials typically 4–12 weeks).

Dose Range: 5–10 mg daily (standard); 15–20 mg daily (advanced, under supervision).

Reconstitution: 3.0 mL per 50 mg vial (~16.67 mg/mL) for convenient single‑syringe administration at standard doses.

Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); use within 4 weeks.

Dosing Protocol

Suggested daily titration approach based on clinical trial protocols[4][5].

Start: 5 mg daily for Weeks 1–2 to assess individual tolerance.

Standard Target: 10 mg daily by Week 3 (most common clinical trial dose).

Advanced Target: 15–20 mg daily for Weeks 5+ (only for severe conditions under medical oversight).

Frequency: Once per day (subcutaneous injection); maintain consistent timing.

Cycle Length: 8–12 weeks; limited data exists beyond 12 weeks.

Timing: Any consistent time; rotate injection sites to prevent tissue irritation.

Storage Instructions

Proper storage preserves peptide stability and potency.

Lyophilized: Store at −20 °C (−4 °F) in original sealed vial; keep dry and protected from light. Stable for months when frozen.

Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) immediately after mixing; use within 4 weeks for optimal stability.

Avoid freeze–thaw: Do not refreeze reconstituted solution; prepare aliquots if needed to minimize temperature fluctuations.

Allow refrigerated vials to reach room temperature before opening to reduce condensation inside the vial.

Important Notes

Practical considerations for consistency, safety, and tolerability.

Use new sterile insulin syringes for each injection; dispose in a sharps container immediately after use.

Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation and prevent lipohypertrophy[14].

Inject slowly over several seconds; wait briefly before withdrawing the needle to prevent leakage.

Mild injection‑site reactions (redness, itching, transient discomfort) are the most common side effects reported in clinical trials[4][6]; these typically resolve within hours.

Document daily dose, injection site, and any adverse reactions to maintain consistency and identify patterns.

For doses requiring split injections (20 mg at this concentration), space injections at least 2 inches apart on different body regions.

How This Works

SS‑31 (elamipretide) is a cell‑permeable tetrapeptide with a unique mechanism of action targeting mitochondrial dysfunction[1]. The peptide selectively accumulates in the inner mitochondrial membrane where it binds to cardiolipin, a specialized phospholipid essential for organizing electron transport chain supercomplexes and maintaining cristae structure[2][7]. By stabilizing cardiolipin‑protein interactions, SS‑31 optimizes electron transport efficiency, reduces pathological reactive oxygen species generation, and enhances ATP synthesis in metabolically active tissues[8].

Preclinical research demonstrated that SS‑31 protects against mitochondrial dysfunction across multiple disease models including heart failure, ischemia‑reperfusion injury, neurodegeneration, chronic kidney disease, and age‑related muscle atrophy[9]. In human clinical trials, SS‑31 showed favorable safety and tolerability profiles with no dose‑limiting toxicities[4][5]. While Phase II trials in heart failure and primary mitochondrial myopathy did not meet primary efficacy endpoints, the TAZPOWER trial in Barth syndrome demonstrated significant improvements in muscle strength and six‑minute walk distance, leading to FDA accelerated approval in 2025[3][10].

Potential Benefits & Side Effects

Observations from preclinical models and human clinical trials.

Potential Benefits:

Stabilizes mitochondrial membranes and optimizes electron transport chain function[1][2].

Enhances ATP production and reduces pathological reactive oxygen species in metabolically active tissues[8].

Demonstrated functional improvements in Barth syndrome patients (increased muscle strength, improved exercise capacity)[3][10].

Shows protective effects in preclinical models of heart failure, neurodegenerative disease, and age‑related muscle atrophy[9].

Does not significantly alter blood pressure, heart rate, or standard laboratory parameters in clinical trials[4].

Common Side Effects:

Injection‑site reactions (most common): Mild‑to‑moderate redness, itching, or transient discomfort at injection site; typically resolves within hours[4][6].

Approximately 80% of patients in clinical trials experienced mild injection‑site reactions[6].

No dose‑limiting toxicities or serious adverse events directly attributed to SS‑31 in published trials[4][5].

Long‑term safety data beyond 12 weeks remains limited; extended use requires monitoring.

Lifestyle Factors

Complementary strategies to support mitochondrial health and optimize outcomes.

Nutrition: Emphasize mitochondrial cofactors including B‑vitamins, CoQ10, magnesium, and alpha‑lipoic acid; maintain adequate protein intake to support muscle maintenance.

Exercise: Combine resistance training with aerobic activity to stimulate mitochondrial biogenesis and enhance oxidative capacity; tailor intensity to individual tolerance.

Sleep: Prioritize 7–9 hours of quality sleep to support cellular repair processes and optimize mitochondrial turnover through autophagy.

Stress Management: Chronic stress increases oxidative burden; incorporate stress‑reduction practices such as meditation, breathwork, or yoga.

Avoid Mitotoxins: Minimize exposure to substances that impair mitochondrial function, including excessive alcohol, certain medications (when possible), and environmental toxins.

Injection Technique

General subcutaneous injection guidance from clinical best‑practice resources[11][12].

Site Preparation: Clean the vial stopper and injection site with alcohol swabs; allow to air‑dry completely (30–60 seconds) before proceeding[13].

Drawing the Dose: Use a new sterile insulin syringe for each injection; draw the prescribed volume from the refrigerated vial; remove any visible air bubbles by gently tapping the syringe.

Injection Angle: Pinch a fold of skin (approximately 1–2 inches); insert the needle at 45–90° depending on subcutaneous tissue thickness (90° for most adults; 45° if very lean)[11][12].

Administration: Do not aspirate for subcutaneous injections[11]; inject slowly and steadily over 3–5 seconds; wait 5–10 seconds before withdrawing the needle to minimize leakage.

Site Rotation: Rotate systematically between injection sites (abdomen at least 2 inches from navel, outer thighs, upper arms, upper buttocks) to prevent lipohypertrophy and local irritation[14].

Post‑Injection: Apply gentle pressure with a clean alcohol swab or cotton ball for a few seconds; do not massage the site vigorously. A small bandage may be applied if needed.

Disposal: Immediately place used syringes in a designated sharps container; never recap needles or dispose of them in regular trash.

Important Note

This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment. SS‑31 is currently FDA‑approved only for Barth syndrome under the brand name Forzinity; use for other conditions remains investigational. Always consult with qualified healthcare professionals before beginning any peptide protocol.

References

International Journal of Molecular Sciences (MDPI) — Elamipretide: comprehensive review of structure, mechanism of action, and therapeutic potential View Source

British Journal of Pharmacology (PMC) — Cardiolipin‑binding mechanism and mitochondrial membrane stabilization by SS‑31 View Source

U.S. Food & Drug Administration (FDA) — FDA grants accelerated approval to elamipretide (Forzinity) as first treatment for Barth syndrome (2025) View Source

Journal of the American College of Cardiology (JACC) — PROGRESS‑HF trial: safety and tolerability of elamipretide in heart failure patients View Source

Neurology (AAN Journals) — MMPOWER‑2 trial: elamipretide in primary mitochondrial myopathy View Source

Genetics in Medicine (Nature) — TAZPOWER trial: efficacy and safety of elamipretide in Barth syndrome View Source

Biochimica et Biophysica Acta (BBA) – Bioenergetics — Cardiolipin remodeling and cristae structure: role in mitochondrial function View Source

Journal of Cardiovascular Pharmacology (PMC) — SS‑31 reduces oxidative stress and improves mitochondrial bioenergetics View Source

Alzheimer’s Drug Discovery Foundation — Cognitive Vitality Report: SS‑31 (elamipretide) preclinical and clinical overview View Source

Orphanet Journal of Rare Diseases (PMC) — Barth syndrome: clinical presentation, diagnosis, and emerging therapies View Source

Centers for Disease Control and Prevention (CDC) — Vaccine administration: subcutaneous injection technique (angle, site selection, no aspiration) View Source

Johns Hopkins Arthritis Center — Patient guide: how to give a subcutaneous injection (step‑by‑step instructions) View Source

NCBI Bookshelf (StatPearls) — Best practices for injection: aseptic technique, preparation, and administration View Source

Pharmacologic Considerations of Subcutaneous Drug Administration (PMC) — Site rotation, absorption kinetics, and prevention of lipohypertrophy View Source

Related research, protocols, and guides

Explore the available research context, protocol variants or comparisons, and practical guides. When vial-size variants exist, they remain separate because vial strength, concentration, and syringe-unit calculations can differ. Related compounds and blends are comparisons only, not interchangeable.

Research overview

SS-31 Peptide: Benefits, Uses, Side Effects, Dosage, and Research

Other vial-size protocols

SS-31 (10 mg Vial) Dosage Protocol

SS-31 (30 mg Vial) Dosage Protocol

Related protocols and comparisons

Glutathione (600 mg Vial) Dosage Protocol

Practical guides

Single Peptide Dosages

Peptide Dosage & Reconstitution Calculator

How to Reconstitute Peptides

Syringe & Measurement Guide

Peptide Storage Guide

Peptide Dosage Chart